Endo Gets Surprise Aveed Approval, But REMS Could Be A Roadblock
This article was originally published in The Pink Sheet Daily
Executive Summary
After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.
You may also be interested in...
Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval
US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.
Testosterone Replacement Safety Gets FDA Panel Review As Lawsuits Pile Up
Two advisory committees will discuss appropriate population for testosterone treatment and potential for adverse cardiovascular outcomes; product liability suits have been consolidated in Illinois federal court.
Endo Follows Valeant’s Strategy Of Growth Through Acquisition
The specialty pharma’s CFO highlighted Endo’s recent restructuring and talked about its plans for M&A going forward at a recent health care conference.